Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine versus placebo for prevention of recurrence in recurrent major depressive disorder
2004-000167-95Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in major depressive disorder (MDD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to recurrence. Started Dec 2004; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-000167-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000167-95.